Entia Biosciences ERGO · USD

Its shares trade under the ticker ERGO. It has been listed since 1 November 2007. In the fiscal year to 31 December 2016, it reported revenue of $265,466 and a net loss of $1.5m. At that date it held total assets of $439,141 and shareholders' equity of −$2.0m.

Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Marvin HausmanChairman of the Board, Chief Technology Officer, Chief Scientific Officer, since 2008$293,697
• Mr. Timothy TimminsPresident, Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Executive Vice President$144,986
• Mr. Elliot SheltonSecretary, Director, since 2008

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.